Skip to content

Clinical Study of Umbilical Cord Blood Mononuclear Cells (UCB-MNCs) in the Treatment of Traumatic Fracture Healing

Clinical Study of Umbilical Cord Blood Mononuclear Cells (UCB-MNCs) in Promoting Traumatic Fracture Healing

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04997590
Enrollment
40
Registered
2021-08-09
Start date
2020-12-10
Completion date
2022-12-10
Last updated
2021-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Nonunion

Keywords

Umbilical cord blood mononuclear cells, Traumatic fracture healing, Bone nonunion

Brief summary

The aim of this study is to explore the effectiveness and safety of umbilical cord blood mononuclear cells in promoting traumatic fracture healing.

Detailed description

Umbilical cord blood mononuclear cells are a type of cell group containing hematopoietic stem cells, mesenchymal stem cells, neural stem cells, endothelial cells, immune cells, etc.In this study ,umbilical cord blood mononuclear cells will be used in promoting traumatic fracture healing,and the effectiveness and safety of the treatment plan was evaluated by twelve months of follow-up after treatment.

Interventions

injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 2 week for a total of 3 times.

DRUGStaphylococcal Enterotoxin C

injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.

Sponsors

Shandong Qilu Stem Cells Engineering Co., Ltd.
CollaboratorINDUSTRY
Qianfoshan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Traumatic long bone fracture. * Noninfectious bone nonunion, delayed bone union. * 3 months after the operation of the fracture, the examination showed no callus growth, no signs of progressive repair at the fracture site, fracture piece space \< 5mm. * No shortening, angulation and displacement. * There was no obvious callus growth 8 months after local bone grafting.

Exclusion criteria

* There are infection foci at and near the fracture end after fracture. * 3 months after the fracture, tests showed partial callus growth. * Combining shortening, angulation and displacement phenomena. * Partial callus grew 8 months after local bone grafting.

Design outcomes

Primary

MeasureTime frameDescription
Bone formation1 month to 1 year after treatmentIf there is no bone formation, 0 points. Bone formation accounts for 25% of the fracture area, 1 point. Bone formation accounts for 50% of the fracture area, 2 points. Bone formation accounts for 75% of the fracture area, 3 points. Bone filled the gap between fracture ends, 4 points.
Bone defect connection1 month to 1 year after treatment0 points for complete fracture lines, 2 points for partial fracture lines, 4 points for lack of fracture lines.
Bone reconstruction1 month to 1 year after treatment0 points for no manifestations of reconstruction,2 points for intramedullary cavity can be reconstructed , and 4 points for the cortical bone can be completely reconstructed. A total score of 11 points or more achieves a good healing effect.

Countries

China

Contacts

Primary ContactChunming Zhang, doctor
liangjing0531@163.com+8618663761275

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026